http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008058126-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2434946a393ffbac0f371a7e81da5ab6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_867a8ff21706d17cf5bb5fbce4779692
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf333e4fc2ddf96d6d6077f516f8830e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7b0bcba4f43756e25188be872100cb1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_481e3f18ae6f80e63f1e2875bd06e478
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
filingDate 2007-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eba953106e6a3e383233c418841cc784
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c7d31ce94f16f69951a9cd4d800a8b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c61943c7ed1d675ac5157f1a3a5d9877
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3ba490a0775a76c1d485434e83ff0bb
publicationDate 2008-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2008058126-A3
titleOfInvention Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
abstract The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II), or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.
priorityDate 2006-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102006029447-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004058769-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408991
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226430550
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425635390
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136599
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11636795
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419524544

Total number of triples: 34.